☆ 4.6 Review

Autoimmune bullous diseases during COVID-19 pandemic: 2022 update on rituximab and vaccine

FRONTIERS IN MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Dermatology

Eosinophil-rich linear IgA bullous dermatosis induced by mRNA COVID-19 booster vaccine

William J. Nahm et al.

Summary: This case presents a rare autoimmune blistering reaction, eosinophil-rich linear IgA bullous disease (LABD), following COVID-19 booster vaccine administration. It highlights the importance of recognizing potential adverse cutaneous reactions from vaccination and the need for additional diagnostic studies to confirm autoimmune blistering diseases.

JOURNAL OF CUTANEOUS PATHOLOGY (2023)

Add to Collection

Letter Dermatology

Severe bullous pemphigoid following Covid-19 vaccination resistant to rituximab and successfully treated with dupilumab

Maria E. Baffa et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2023)

Add to Collection

Letter Dermatology

COVID-19 in pemphigus vulgaris patients with previous rituximab therapy: a tele-medicine experience

Mohammad Shahidi-Dadras et al.

JOURNAL OF DERMATOLOGICAL TREATMENT (2022)

Add to Collection

Letter Dermatology

An unusual presentation of pemphigus foliaceus following COVID-19 vaccination

Angelyn Chen Yin Lua et al.

AUSTRALASIAN JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Letter Dermatology

Bullous pemphigoid after SARS-CoV-2 vaccination: spike-protein-directed immunofluorescence confocal microscopy and T-cell-receptor studies

T. Gambichler et al.

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Letter Dermatology

COVID-19 vaccine acceptance and hesitancy in patients with immunobullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation

M. Kasperkiewicz et al.

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Letter Dermatology

Linear IgA bullous dermatosis following Oxford AstraZeneca COVID-19 vaccine

F. Hali et al.

Summary: This case suggests a possible causal association between the COVID-19 vaccine and linear IgA bullous dermatosis, highlighting the importance of monitoring for immune-mediated bullous diseases following vaccination.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

Add to Collection

Review Dermatology

COVID vaccination in patients under treatment with rituximab: A presentation of two cases from Iran and a review of the current knowledge with a specific focus on pemphigus

Parvaneh Hatami et al.

Summary: SARS-COV2 vaccines were approved in emergent situations without long-term monitoring, raising concerns about timing and protocols. Individualized risk assessment and delaying rituximab administration post-vaccination, as well as choosing vaccines with single-dose potential for protection, may be practical recommendations for clinicians in managing patients.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

Bullous pemphigoid triggered by COVID-19 vaccine: Rapid resolution with corticosteroid therapy

Massimo Dell'Antonia et al.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Article Dermatology

Pemphigus vulgaris relapse during the coronavirus disease pandemic

Marwah Adly Saleh et al.

Summary: During the COVID-19 pandemic, the treatment of relapsing PV patients included systemic steroids, immunosuppressive drugs, and rituximab. These treatments were well tolerated and resulted in remission without major adverse effects.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin

Ecem Bostan et al.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

New onset of pemphigus foliaceus following BNT162b2 vaccine

Sebnem Yildirici et al.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Article Dermatology

Pemphigus vulgaris after SARS-CoV-2 vaccination: A case with new-onset and two cases with severe aggravation

Gulsen Akoglu

Summary: This article reports a case of new-onset pemphigus vulgaris (PV) and two cases with aggravation of PV after vaccinations for SARS-CoV-2. The worldwide vaccination with SARS-CoV-2 vaccines may be associated with increased incidence of autoimmune bullous diseases in individuals with underlying genetic predisposition.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

Can Covid-19 vaccines cause or exacerbate bullous pemphigoid? A report of seven cases from one center

Elif Afacan et al.

INTERNATIONAL JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Letter Dermatology

Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study

Pascal Joly et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Add to Collection

Letter Dermatology

Bullous pemphigoid in a young male after COVID-19 mRNA vaccine: a report and brief literature review

M. Pauluzzi et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Letter Dermatology

Biphasic bullous pemphigoid starting after first dose and boosted by second dose of mRNA-1273 vaccine in an 84-year-old female with polymorbidity and polypharmacy

V. Schmidt et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Letter Dermatology

Development of pemphigus vulgaris following mRNA SARS-CoV-19 BNT162b2 vaccination in an 89-year-old patient

G. V. Knechtl et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Letter Dermatology

Psoriasis flare-up after AZD1222 and BNT162b2 COVID-19 mRNA vaccines: report of twelve cases from a single centre

D. Koumaki et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Letter Dermatology

Incident bullous pemphigoid in a psoriatic patient following mRNA-1273 SARS-CoV-2 vaccination

W. -K. Hung et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Letter Dentistry, Oral Surgery & Medicine

Oral pemphigus after COVID-19 vaccination

Kobkan Thongprasom et al.

ORAL DISEASES (2022)

Add to Collection

Letter Dentistry, Oral Surgery & Medicine

Development of pemphigus vulgaris after the second dose of the mRNA-1273 SARS-Cov-2 vaccine

Ioannis G. Koutlas et al.

ORAL DISEASES (2022)

Add to Collection

Letter Dermatology

Vesiculobullous skin reactions induced by COVID-19 mRNA vaccine: report of four cases and review of the literature

P. Coto-Segura et al.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2022)

Add to Collection

Letter Dermatology

Bullous pemphigoid induced by the AstraZeneca COVID-19 vaccine

F. -Z Agharbi et al.

ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE (2022)

Add to Collection

Letter Dermatology

Evaluating risk of bullous pemphigoid after mRNA COVID-19 vaccination

Morgan Birabaharan et al.

BRITISH JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

COVID-19 severity and SARS-Cov-2 vaccine safety in pemphigus patients

Zuleyha Ozgen et al.

Summary: This study investigated the disease characteristics and demographic features of pemphigus patients during the COVID-19 pandemic, aiming to assess the impact of immunosuppressants on the course of COVID-19 in this patient group. The results showed that most patients had a non-serious disease, although a small number required hospitalization.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

Bullous pemphigoid after inactivated COVID-19 vaccination: Case report

Yingjie Zhang et al.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

Reply to New-onset bullous pemphigoid after inactivated Covid-19 vaccine: Synergistic effect of the Covid-19 vaccine and vildagliptin

Carlo Alberto Maronese et al.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

De novo severe pemphigus vulgaris following SARS-CoV-2 vaccination with BBIBP-CorV

Zahra Saffarian et al.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

New-onset bullous pemphigoid and flare of pre-existing bullous pemphigoid after the third dose of the COVID-19 vaccine

Federico Bardazzi et al.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Article Dermatology

Clinical and histopathological spectrum of delayed adverse cutaneous reactions following COVID-19 vaccination

Valerie Larson et al.

Summary: This retrospective case series reviewed cutaneous adverse reactions to mRNA-based COVID-19 vaccines, identifying various skin manifestations including injection-site reactions, generalized eruptions, and eczematous dermatitis. The study suggests that dermatopathologists should be aware of potential cutaneous adverse reactions to COVID-19 vaccines, with histopathological patterns ranging from mixed-cell infiltrates to epidermal spongiosis and interface changes.

JOURNAL OF CUTANEOUS PATHOLOGY (2022)

Add to Collection

Article Dermatology

Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study

Devon E. McMahon et al.

Summary: This study investigated histopathologic features and clinical correlations of cutaneous reactions after COVID-19 vaccination, proposing the concept of V-REPP (vaccine-related eruption of papules and plaques) and 12 other reaction patterns. Despite limitations in available biopsy reports, the research provided new insights into skin reactions following vaccination.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

Add to Collection

Letter Dermatology

A case of bullous pemphigoid after the SARS-CoV-2 mRNA vaccine

J. Young et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Letter Dermatology

Association between vaccination and immunobullous disorders: a brief, updated systematic review with focus on COVID-19

M. Kasperkiewicz et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Review Pathology

Autoimmune mucocutaneous blistering diseases after SARS-Cov-2 vaccination: A Case report of Pemphigus Vulgaris and a literature review

Elena Calabria et al.

Summary: This study reported a case of oropharyngeal pemphigus vulgaris triggered by the SARS-CoV-2 vaccination and analyzed the clinical and immunological characteristics of AIBDs cases reported after the vaccination. A total of 35 cases of AIBDs triggered by the vaccination were found, with bullous pemphigoid being the most common diagnosis. Despite the potential risk of AIBDs after vaccination, clinicians should encourage patients to get vaccinated to help combat the COVID-19 pandemic.

PATHOLOGY RESEARCH AND PRACTICE (2022)

Add to Collection

Editorial Material Dermatology

Development of severe pemphigus vulgaris following ChAdOx1 nCoV-19 vaccination and review of literature

Ajeet Singh et al.

Summary: This article reports a case of severe pemphigus vulgaris following the second dose of ChAdOx1 nCoV-19 vaccination in an adult male. The patient developed septicemia during hospitalization and showed improvement after receiving systemic steroids, antibiotics, and intravenous immunoglobulins (IVIg).

JOURNAL OF COSMETIC DERMATOLOGY (2022)

Add to Collection

Article Immunology

Autoimmune Skin Disease Exacerbations Following COVID-19 Vaccination

Grant Sprow et al.

Summary: The study found that fully vaccinated dermatomyositis patients were more likely to report exacerbation of autoimmune signs and symptoms after vaccination compared to fully vaccinated lupus erythematosus patients. However, given the risks of COVID-19, clinicians should still promote vaccination in most patients with autoimmune skin disease.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Bullous Pemphigoid Associated With COVID-19 Vaccines: An Italian Multicentre Study

Carlo Alberto Maronese et al.

Summary: Bullous pemphigoid (BP) is an autoimmune disease that COVID-19 vaccines may induce. An Italian study collected data of BP patients associated with COVID-19 vaccines and found that these patients have similar characteristics to idiopathic BP, but with a slight male predominance and reduced humoral response to BP230.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Article Rheumatology

Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies

Laura Boekel et al.

Summary: This study aimed to compare the incidence and severity of SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases using immunosuppressants and controls, as well as explore the determinants of breakthrough infections, including humoral immune responses after vaccination. The study found that the incidence and severity of breakthrough infections in patients on immunosuppressants were similar to those in controls. However, caution might still be warranted for those on anti-CD20 therapy and those with traditional risk factors.

LANCET RHEUMATOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Bullous pemphigoid after second dose of mRNA- (Pfizer-BioNTech) Covid-19 vaccine: A case report

Fouad Alshammari et al.

Summary: This article describes a case of bullous fixed medication eruption following the second dose of Pfizer's COVID-19 vaccine. While common adverse effects of COVID-19 vaccines are known, such as headache and muscle soreness, little is understood about dermatological side effects.

ANNALS OF MEDICINE AND SURGERY (2022)

Add to Collection

Article Dermatology

Adverse outcome and severity of COVID-19 in patients with autoimmune bullous diseases: A historical cohort study

Fateme Shirzad Moghadam et al.

Summary: This study evaluated the outcome of COVID-19 infection in patients with autoimmune bullous dermatoses (AIBDs) and its correlation with the drugs used for AIBDs treatment. The results showed that comorbidities and higher prednisolone dosage were associated with increased severity of COVID-19, while vaccination and longer interval from the last rituximab infusion were associated with decreased severity. Some patients experienced AIBD flare-ups following COVID-19 infection.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Article Dermatology

Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases

Safoura Shakoei et al.

Summary: This study evaluated patients who developed skin manifestations after receiving COVID-19 vaccines, and found various skin diseases. It was also observed that Sinopharm vaccine was more associated with skin manifestations. The study highlights the importance for physicians to be aware of the potential side effects, particularly cutaneous manifestations, of COVID-19 vaccines.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

Influence of Covid-19 vaccination on immune-mediated skin diseases

N. A. Alelq et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Letter Dermatology

Cutaneous adverse reactions following SARS-CoV-2 vaccine booster dose: a real-life multicentre experience

G. Avallone et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Exacerbation of Autoimmune Bullous Diseases After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination: Is There Any Association?

Nika Kianfar et al.

Summary: This study evaluated the safety of COVID-19 vaccination in patients with AIBDs and found that the risk of disease exacerbation after vaccination is not high, but can be reduced if the disease is controlled at the time of vaccination.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Article Rheumatology

Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform

Brian MacKenna et al.

Summary: This study aimed to assess the risk of severe COVID-19 outcomes in adults with immune-mediated inflammatory diseases and on immune-modifying therapies. The findings showed that adults with immune-mediated inflammatory diseases had an increased risk of COVID-19-related death, critical care admission or death, and hospital admission compared to the general population, but most targeted immune-modifying drugs did not increase the risk of adverse COVID-19 outcomes.

LANCET RHEUMATOLOGY (2022)

Add to Collection

Letter Dermatology

New onset of pemphigus foliaceus following BBIBP COVID-19 vaccine

Mohammadreza Pourani et al.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Article Dermatology

Five cases of new-onset pemphigus following vaccinations against coronavirus disease 2019

Alberto Corra et al.

Summary: This paper reports several cases of pemphigus occurring after COVID-19 vaccination, suggesting a possible causal correlation.

JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Article

A new eruption of bullous pemphigoid following mRNA COVID-19 vaccination

Bryan Daines et al.

Dermatology Online Journal (2022)

Add to Collection

Letter Dermatology

New-onset bullous pemphigoid triggered by AstraZeneca COVID-19 vaccine

Yin-Cheng Chao et al.

DERMATOLOGICA SINICA (2022)

Add to Collection

Review Medicine, General & Internal

Association between COVID-19 vaccination and bullous pemphigoid a case series and literature review

Vincent Wan et al.

Summary: This study reported two cases of new-onset bullous pemphigoid after COVID-19 vaccination and conducted a brief literature review. The results showed that new-onset bullous pemphigoid may develop following COVID-19 vaccinations. Entering a period of clinical remission before subsequent COVID-19 vaccinations and close follow-up should be considered to lessen the risk of recurrences or exacerbations.

SAGE OPEN MEDICAL CASE REPORTS (2022)

Add to Collection

Article Medicine, General & Internal

Dyshidrosiform Bullous Pemphigoid Triggered by COVID-19 Vaccination

Mohammed Shanshal

Summary: Vaccination has significantly improved global health, but COVID-19 vaccinations can cause various adverse skin reactions. A rare clinical variant of bullous pemphigoid, dyshidrosiform bullous pemphigoid, was observed in an elderly female patient following COVID-19 vaccination.

CUREUS JOURNAL OF MEDICAL SCIENCE (2022)

Add to Collection

Article Medicine, General & Internal

Bullous Pemphigoid Following the Moderna mRNA-1273 Vaccine

Amar D. Desai et al.

Summary: With the emergence of novel variants of the SARS-CoV-2 virus, widespread vaccination efforts may lead to an increased number of severe cutaneous adverse reactions. However, there is limited data on which reactions are most common and how to manage them in different populations. This case report presents a unique systemic bullous pemphigoid reaction in a 73-year-old female following Moderna vaccination, which has not been reported in elderly, postmenopausal women in the United States.

CUREUS JOURNAL OF MEDICAL SCIENCE (2022)

Add to Collection

Article Medicine, General & Internal

Autoimmune Bullous Dermatosis Following COVID-19 Vaccination: A Series of Five Cases

Fouzia Sr Hali et al.

Summary: Autoimmune bullous diseases (AIBDs) are a group of heterogeneous diseases characterized by vesicles, blisters, and erosions on the skin and mucous membranes. Vaccination against COVID-19 can potentially trigger an immune response in genetically predisposed individuals. We report five cases of new-onset autoimmune bullous diseases triggered by the COVID-19 vaccine. According to the French method of imputability, the vaccines were highly probable as the cause for all patients.

CUREUS JOURNAL OF MEDICAL SCIENCE (2022)

Add to Collection

Letter Dermatology

An unusual presentation of pemphigus foliaceus following COVID-19 vaccination

Angelyn Chen Yin Lua et al.

AUSTRALASIAN JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Letter Rheumatology

Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia

Philippe Guilpain et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Rheumatology

Response to: 'Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab' by Avouac et al

Philippe Guilpain et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Letter Dermatology

COVID-19 outbreak and autoimmune bullous diseases: A systematic review of published cases

Michael Kasperkiewicz

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Review Virology

Predictors ofCOVID-19 severity: A literature review

Benjamin Gallo Marin et al.

Summary: The severity and mortality of COVID-19 may be associated with patient age, multiple comorbidities, hypoxia, extensive lung involvement on CT scans, laboratory abnormalities, and biomarkers of end-organ dysfunction.

REVIEWS IN MEDICAL VIROLOGY (2021)

Add to Collection

Article Dermatology

Can rituximab be used in the treatment of pemphigus vulgaris during the COVID-19 pandemic?

Tugba Kevser Uzuncakmak et al.

Summary: The study found that pemphigus patients who have received rituximab treatment within the previous 5 years have a lower risk of COVID-19 infection, regardless of the number of treatment courses or the duration since treatment. The disease course was mild in the only infected patient, suggesting that rituximab may be used for pemphigus treatment during the COVID-19 pandemic if necessary.

DERMATOLOGIC THERAPY (2021)

Add to Collection

Letter Dermatology

Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: A retrospective cohort study

Hamidreza Mahmoudi et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

SARS-CoV-2 Infection Hospitalization Rate and Infection Fatality Rate Among the Non-Congregate Population in Connecticut

Shiwani Mahajan et al.

Summary: The study found that the COVID-19 infection hospitalization rate and infection fatality rate in the non-congregate population in Connecticut were estimated to be 6.86% and 0.95% respectively, with older people, men, non-Hispanic Black people, and residents from two counties bearing a higher burden of adverse outcomes, although most subgroup differences were not statistically significant.

AMERICAN JOURNAL OF MEDICINE (2021)

Add to Collection

Article Rheumatology

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Anja Strangfeld et al.

Summary: Factors associated with COVID-19-related death in people with rheumatic diseases include age, sex, comorbidities, disease activity, and specific medications. Adequate disease control with disease-modifying anti-rheumatic drugs (DMARDs) without increasing glucocorticoid dosages is important, while caution may be required with certain medications such as rituximab and sulfasalazine.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Immunology

The SARS-CoV-2 as an instrumental trigger of autoimmunity

Arad Dotan et al.

Summary: This article emphasizes the association between COVID-19 and the development of multiple types of autoantibodies and autoimmune diseases in patients. It highlights the potential molecular resemblance between SARS-CoV-2 and host self-components, leading to hyper-stimulation of the immune system. Recognizing autoimmune manifestations of COVID-19 is crucial for managing the ongoing pandemic and its long-term consequences.

AUTOIMMUNITY REVIEWS (2021)

Add to Collection

Letter Rheumatology

SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response

Michael Markus Bonelli et al.

ANNALS OF THE RHEUMATIC DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Inactivated COVID-19 Vaccine Induces a Low Humoral Immune Response in a Subset of Dermatological Patients Receiving Immunosuppressants

Chutima Seree-aphinan et al.

Summary: The study found that dermatological patients on certain immunosuppressive drugs had lower levels of immune response to the Sinovac-CoronaVac vaccine, while those on other medications or biologics had similar immunogenic profiles to those not receiving immunosuppressive therapy. Although not statistically significant, a reduction in humoral immune response was observed in patients using two or more immunosuppressants or those with pemphigus. These findings suggest that some patients with immune-mediated skin conditions may benefit from vaccines that elicit a higher level of immunogenicity or booster doses.

FRONTIERS IN MEDICINE (2021)

Add to Collection

Article Dermatology

The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study

Khalaf Kridin et al.

Summary: The study found that patients with bullous pemphigoid have an increased risk of COVID-19-associated mortality, while patients with pemphigus have similar risks as their controls. The use of systemic corticosteroids and immunosuppressants did not predispose patients to more severe illness from COVID-19.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)

Add to Collection

Letter Dermatology

COVID-19 pandemic and autoimmune bullous diseases: a cross-sectional study of the International Pemphigus and Pemphigoid Foundation

M. Kasperkiewicz et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection

Article Immunology

Case Report: Complete and Fast Recovery From Severe COVID-19 in a Pemphigus Patient Treated With Rituximab

Jo Linda Sinagra et al.

Summary: Managing patients with chronic autoimmune diseases during the COVID-19 pandemic is challenging due to the risks associated with the conditions themselves and drug-induced immunosuppression. In the case of pemphigus patients, immunosuppressant therapies like rituximab can pose a risk of increased susceptibility to infections, despite being highly effective treatments.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Letter Dermatology

COVID-19 outcomes in patients with autoimmune blistering disease

E. Hwang et al.

BRITISH JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Editorial Material Allergy

Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination

Mary M. Tomayko et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Letter Dermatology

Case of bullous pemphigoid following coronavirus disease 2019 vaccination

Kenta Nakamura et al.

JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Letter Dermatology

Development of severe pemphigus vulgaris following SARS-CoV-2 vaccination with BNT162b2

F. Solimani et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection

Letter Dermatology

The first dose of COVID-19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?

G. Damiani et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy

Giacomo Grasselli et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Virology

The value of clinical parameters in predicting the severity of COVID-19

Weifeng Shang et al.

JOURNAL OF MEDICAL VIROLOGY (2020)

Add to Collection

Letter Dermatology

Should SARS-CoV-2 influence immunosuppressive therapy for autoimmune blistering diseases?

A. Di Altobrando et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

Add to Collection

Letter Dermatology

Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic

M. Kasperkiewicz et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

Add to Collection

Letter Dermatology

Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus

R. Balestri et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Fei Zhou et al.

LANCET (2020)

Add to Collection

Letter Dermatology

Patients with bullous skin disease in a high-epidemic COVID-19 area, Bergamo, Italy

A. Carugno et al.

BRITISH JOURNAL OF DERMATOLOGY (2020)

Add to Collection

Article Rheumatology

Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?

Ennio Giulio Favalli et al.

ARTHRITIS & RHEUMATOLOGY (2020)

Add to Collection

Article Critical Care Medicine

Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study

Christian Karagiannidis et al.

LANCET RESPIRATORY MEDICINE (2020)

Add to Collection

Article Infectious Diseases

Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics

Eskild Petersen et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Article Multidisciplinary Sciences

Factors associated with COVID-19-related death using OpenSAFELY

Elizabeth J. Williamson et al.

NATURE (2020)

Add to Collection

Letter Dermatology

Aggressive course of pemphigus vulgaris following COVID-19 infection

Fariba Ghalamkarpour et al.

DERMATOLOGIC THERAPY (2020)

Add to Collection

Article Rheumatology

Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs

Xabier Michelena et al.

SEMINARS IN ARTHRITIS AND RHEUMATISM (2020)

Add to Collection

Article Rheumatology

High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study

Jesus Loarce-Martos et al.

RHEUMATOLOGY INTERNATIONAL (2020)

Add to Collection

Letter Rheumatology

Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease

Chia Siang Kow et al.

RHEUMATOLOGY INTERNATIONAL (2020)

Add to Collection

Article Dermatology

Efficacy of Repeated Courses of Rituximab as Treatment for Pemphigus Vulgaris

Sharon Baum et al.

ACTA DERMATO-VENEREOLOGICA (2020)

Add to Collection

Article Multidisciplinary Sciences

Age-specific mortality and immunity patterns of SARS-CoV-2

Megan O'Driscoll et al.

NATURE (2020)

Add to Collection

Review Rheumatology

Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations

Christien Rondaan et al.

RMD OPEN (2019)

Add to Collection

Article Dermatology

Exacerbation of pemphigus after influenza vaccination

C. De Simone et al.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2008)

Add to Collection

Article Immunology

Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice

David J. DiLillo et al.

JOURNAL OF IMMUNOLOGY (2008)

Add to Collection

Letter Dermatology

Exacerbation of pemphigus foliaceus after tetanus vaccination accompanied by synthesis of auto-antibodies against paraneoplastic pemphigus antigens

K Korang et al.

ACTA DERMATO-VENEREOLOGICA (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.